KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Fulgent Genetics (FLGT) over the last 11 years, with Q2 2025 value amounting to $9.9 million.

  • Fulgent Genetics' Asset Writedowns and Impairment rose 69795.18% to $9.9 million in Q2 2025 from the same period last year, while for Sep 2025 it was $198000.0, marking a year-over-year decrease of 9788.62%. This contributed to the annual value of -$1.7 million for FY2024, which is 9659.09% down from last year.
  • Fulgent Genetics' Asset Writedowns and Impairment amounted to $9.9 million in Q2 2025, which was up 69795.18% from $2.1 million recorded in Q1 2025.
  • Fulgent Genetics' 5-year Asset Writedowns and Impairment high stood at $11.6 million for Q1 2022, and its period low was -$11.8 million during Q4 2024.
  • Its 5-year average for Asset Writedowns and Impairment is $2.6 million, with a median of $2.1 million in 2021.
  • Per our database at Business Quant, Fulgent Genetics' Asset Writedowns and Impairment skyrocketed by 1561428.57% in 2021 and then crashed by 210973.45% in 2024.
  • Fulgent Genetics' Asset Writedowns and Impairment (Quarter) stood at $4.8 million in 2021, then surged by 51.24% to $7.3 million in 2022, then crashed by 52.7% to $3.5 million in 2023, then crashed by 442.02% to -$11.8 million in 2024, then surged by 184.1% to $9.9 million in 2025.
  • Its Asset Writedowns and Impairment stands at $9.9 million for Q2 2025, versus $2.1 million for Q1 2025 and -$11.8 million for Q4 2024.